Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 646,554 | 600,135 | 461,858 | 535,608 | 263,211 |
| Marketable Securities | 395,650 | 216,774 | 186,275 | 158,376 | 182,112 |
| Receivables | 927,254 | 893,924 | 1,047,496 | 954,967 | 992,824 |
| Inventories | 120,317 | 109,897 | 86,545 | 70,354 | N/A |
| Income taxes - deferred | 49,005 | 37,291 | 36,623 | 44,677 | 39,174 |
| TOTAL | $2,200,512 | $1,918,695 | $1,871,049 | $1,796,934 | $1,634,160 |
| Non-Current Assets | |||||
| PPE Net | 818,967 | 707,321 | 600,864 | 526,983 | 453,891 |
| Investments And Advances | 453,443 | 550,818 | 534,689 | 389,891 | 329,863 |
| Other Non-Current Assets | 266,497 | 279,244 | 253,794 | 237,205 | 222,501 |
| TOTAL | $1,538,907 | $1,537,383 | $1,389,347 | $1,154,079 | $1,006,255 |
| Total Assets | $3,739,419 | $3,456,078 | $3,260,396 | $2,951,013 | $2,640,415 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 337,976 | 283,385 | 237,935 | 250,896 | 219,138 |
| Other current liabilities | N/A | N/A | N/A | 939 | N/A |
| TOTAL | $410,200 | $351,578 | $305,068 | $298,835 | $268,727 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 70,972 | 67,133 | 66,073 | 47,000 | 48,795 |
| aiOther Non-Current Liabilities | 311,697 | 297,229 | 338,467 | 331,645 | 324,735 |
| TOTAL | $777,431 | $735,658 | $744,080 | $700,102 | $681,517 |
| Total Liabilities | $1,187,631 | $1,087,236 | $1,049,148 | $998,937 | $950,244 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 101,665 | 101,066 | 100,881 | 99,928 | 99,419 |
| Common Shares | 102 | 102 | 101 | 99 | 99 |
| Retained earnings | 145,206 | 65,486 | -27,249 | -92,692 | -189,498 |
| Other shareholders' equity | 27,046 | 4,415 | 1,465 | -1,188 | -2,851 |
| TOTAL | $2,551,788 | $2,368,842 | $2,211,248 | $1,952,076 | $1,690,171 |
| Total Liabilities And Equity | $3,739,419 | $3,456,078 | $3,260,396 | $2,951,013 | $2,640,415 |